A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
Active, not recruiting · Phase 3 · NCT06506916
Conditions: Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
At a glance
- Research payments reported, 2025
- $409,802
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 89
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- bimekizumab (drug)
- Dates
- Started 2024-07-29; completion 2028-03-14
- Results posted
- Not yet
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).
From ClinicalTrials.gov, last updated 2026-07-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $409,802 in research payments for this study in 2025 (7 payments).
Products named: Bimzelx
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Boni Elewski Dermatology · Birmingham, AL
- Vivian Laquer, M.D. Dermatology · Irvine, CA
- Paul S. Yamauchi, M.D., PHD Dermatology · Santa Monica, CA
- Seth B. Forman, MD Dermatology · Tampa, FL
- Johann E. Gudjonsson, MD Dermatology · Ann Arbor, MI
- John H. Tu, MD Dermatology · Rochester, NY
- Joe K. Tung, MD, MBA Dermatology · Pittsburgh, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Michigan Health System, MI $179,771
- Skin Search of Rochester Inc $82,530
- University of Pittsburgh Physicians $62,602
- University of Alabama Hospital, AL $37,485
- Forward Clinical Trials Inc $29,814
- First Oc Dermatology Research Inc $14,600
- Clinical Science Institute $3,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.